Limits...
Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.

Jiang L, Jiang S, Situ D, Lin Y, Yang H, Li Y, Long H, Zhou Z - Oncotarget (2015)

Bottom Line: We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience.And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up.For this reason, this result could serve as a basis for future prospective study.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT
Metastatic soft tissue sarcomas (STS) represent enormous challenges to improve the low survival rate, which is almost the same as past 2 decades ago. Prognosis of cancer patients are based not only on tumor-related factors but also on host-related factors, particularly systemic inflammatory response. We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience. We found that both monocyte ratio and NLR ratio were significant prognostic predictors for OS and PFS of metastatic STS. And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up. For this reason, this result could serve as a basis for future prospective study.

No MeSH data available.


Related in: MedlinePlus

OS rate of patients with PFS exceeding 225 days or not. PFS progress-free survival, OS overall survival
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496237&req=5

Figure 1: OS rate of patients with PFS exceeding 225 days or not. PFS progress-free survival, OS overall survival

Mentions: Univariate analysis showed a PFS exceeding 225 days (p = 0.003) as prognostic factors (Fig. 1). Age (P = 0.238), Sex (P = 0.783), size of primary tumor (P = 0.425), tumor depth (P = 0.484), pathological subtypes (P = 0.861) and pathological grade (P = 0.965) did not have any significant impact on OS (Table 2). Median OS was 2411 days and 28.2% of the patients were alive without disease, 25.4% were alive with disease, 45.8% dies of disease, while 0.7% (1 patients) died from other causes (heart disease). The overall 1-, 3- and 5-year OS rates were 88%, 61% and 44% each, respectively (Fig. 2).


Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma.

Jiang L, Jiang S, Situ D, Lin Y, Yang H, Li Y, Long H, Zhou Z - Oncotarget (2015)

OS rate of patients with PFS exceeding 225 days or not. PFS progress-free survival, OS overall survival
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496237&req=5

Figure 1: OS rate of patients with PFS exceeding 225 days or not. PFS progress-free survival, OS overall survival
Mentions: Univariate analysis showed a PFS exceeding 225 days (p = 0.003) as prognostic factors (Fig. 1). Age (P = 0.238), Sex (P = 0.783), size of primary tumor (P = 0.425), tumor depth (P = 0.484), pathological subtypes (P = 0.861) and pathological grade (P = 0.965) did not have any significant impact on OS (Table 2). Median OS was 2411 days and 28.2% of the patients were alive without disease, 25.4% were alive with disease, 45.8% dies of disease, while 0.7% (1 patients) died from other causes (heart disease). The overall 1-, 3- and 5-year OS rates were 88%, 61% and 44% each, respectively (Fig. 2).

Bottom Line: We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience.And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up.For this reason, this result could serve as a basis for future prospective study.

View Article: PubMed Central - PubMed

Affiliation: Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT
Metastatic soft tissue sarcomas (STS) represent enormous challenges to improve the low survival rate, which is almost the same as past 2 decades ago. Prognosis of cancer patients are based not only on tumor-related factors but also on host-related factors, particularly systemic inflammatory response. We evaluated the association among possible risk factors and survival for metastatic STS by reviewed a single-institution nearly 50-year experience. We found that both monocyte ratio and NLR ratio were significant prognostic predictors for OS and PFS of metastatic STS. And patients with monocyte ratio or NLR ratio > 1 should be screened out as candidates for more intensive or aggressive multimodality treatments and more aggressive follow-up. For this reason, this result could serve as a basis for future prospective study.

No MeSH data available.


Related in: MedlinePlus